TY - JOUR
T1 - The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers
AU - Inzelberg, R.
AU - Cohen, O. S.
AU - Aharon-Peretz, J.
AU - Schlesinger, I.
AU - Gershoni-Baruch, R.
AU - Djaldetti, R.
AU - Nitsan, Z.
AU - Ephraty, L.
AU - Tunkel, O.
AU - Kozlova, E.
AU - Inzelberg, L.
AU - Kaplan, N.
AU - Fixler Mehr, T.
AU - Mory, A.
AU - Dagan, E.
AU - Schechtman, E.
AU - Friedman, E.
AU - Hassin-Baer, S.
PY - 2012/3/13
Y1 - 2012/3/13
N2 - Objective: In view of the fact that cancer patterns in patients with Parkinson disease (PD) differ from the general population, we aimed to verify whether patients with PD with LRRK2 mutations have an increased risk for particular cancer types. Methods: In this cross-sectional study, eligible consenting Jewish patients with PD were genotyped for the predominant LRRK2 G2019S mutation. Oncologic data were obtained by personal interview and reviewing patients' files. Stepwise logistic regression was applied to model the probability of cancer occurrence in carriers vs noncarriers. Results: Overall, 79/490 (16.1%) genotyped patients carried the G2019S mutation. Seventyseven (16%) were diagnosed with cancer; of those, 67 (14%) with a non-skin cancer. Eighteen (23%) carriers vs 49 (12%) noncarriers had a non-skin cancer (p = 0.01, odds ratio [OR] = 2.18, 95% confidence interval [CI] 1.19-3.99). A significant ethnicity effect was noted (p = 0.045, OR = 1.84, 95% CI 1.02-3.34). Among Ashkenazi patients, age and LRRK2 emerged as significant using stepwise logistic regression including age, gender, and LRRK2 status as explanatory variables. The OR for LRRK2 mutation carriers adjusted for age was 3.38 (95% CI 1.64-6.97, p = 0.0009).
AB - Objective: In view of the fact that cancer patterns in patients with Parkinson disease (PD) differ from the general population, we aimed to verify whether patients with PD with LRRK2 mutations have an increased risk for particular cancer types. Methods: In this cross-sectional study, eligible consenting Jewish patients with PD were genotyped for the predominant LRRK2 G2019S mutation. Oncologic data were obtained by personal interview and reviewing patients' files. Stepwise logistic regression was applied to model the probability of cancer occurrence in carriers vs noncarriers. Results: Overall, 79/490 (16.1%) genotyped patients carried the G2019S mutation. Seventyseven (16%) were diagnosed with cancer; of those, 67 (14%) with a non-skin cancer. Eighteen (23%) carriers vs 49 (12%) noncarriers had a non-skin cancer (p = 0.01, odds ratio [OR] = 2.18, 95% confidence interval [CI] 1.19-3.99). A significant ethnicity effect was noted (p = 0.045, OR = 1.84, 95% CI 1.02-3.34). Among Ashkenazi patients, age and LRRK2 emerged as significant using stepwise logistic regression including age, gender, and LRRK2 status as explanatory variables. The OR for LRRK2 mutation carriers adjusted for age was 3.38 (95% CI 1.64-6.97, p = 0.0009).
UR - http://www.scopus.com/inward/record.url?scp=84859929853&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e318249f673
DO - 10.1212/WNL.0b013e318249f673
M3 - Article
C2 - 22323743
AN - SCOPUS:84859929853
SN - 0028-3878
VL - 78
SP - 781
EP - 786
JO - Neurology
JF - Neurology
IS - 11
ER -
